U.S. pharmaceutical concern Johnson & Johnson on
Tuesday reported a fall in third quarter net income to $3 billion, or $1.15 a share, down from $3.2 billion in the same
period last year.
The 7.3 percent decline was attributed to increased research and production costs.
Revenues rose to $17.1 billion, a rise of 6.5 percent over the same quarter last year. The stronger dollar hurt the value of foreign sales, which otherwise would have grown 10.8 percent over the same quarter last year, the company said.
Most Popular Stories
- Hernandez lawyer: Pats Records Dispute Resolved
- Honda' s Accord Plug-in Hybrid Is a Fuel Miser
- National Retail Federation Reduces Sales Forecast
- Social Media Startups That Pay You to Post
- Congress Leaving Town as Deadlines Loom
- Female Business Owners Still Face Gender Gap
- Oregon Voters to Decide on Recreational Pot
- Amazon Fire Phone Improves on Familiar: Review
- 4th Circuit Upholds Obamacare Subsidies
- Oregon to Vote on Recreational Marijuana